News & Updates
Filter by Specialty:

Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023
byAudrey Abella
In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.
Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023
Asthma education, control test help lower exacerbations risks
23 Nov 2023
byStephen Padilla
The presence of asthma education and Asthma Control Test (ACT) may prevent exacerbations or at least delay the onset of severe exacerbations, suggests a Singapore study.